Actuate Therapeutics Inc. has announced the publication of new Phase II clinical trial data evaluating elraglusib, a glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in combination with platinum chemotherapy (carboplatin or cisplatin), with or without sequential pembrolizumab immunotherapy, for patients with advanced, metastatic salivary gland cancers. The results, published in Clinical Cancer Research (PMID: 41065505), show a median overall survival of 18.6 months, with 40% of patients alive at two years. The study enrolled 32 patients, including both adenoid cystic carcinoma (47%) and non-ACC (53%) subtypes, in partnership with the Dana-Farber Cancer Institute. Findings suggest that nuclear GSK-3β expression may help identify patients most likely to benefit from this treatment approach. The data have already been published and are available for review.